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 N-myc downstream-regulated gene 2 (Ndrg2) is a differentiation- and stress-associated 
molecule predominantly expressed in astrocytes in the central nervous system (CNS). To study 
the expression and possible role of Ndrg2 in quiescent and activated astrocytes, mice were 
administrated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP), a Parkinson 
disease (PD)-related neurotoxin which causes both neurodegeneration and glial activation. 
Immunohistological analysis revealed that Ndrg2 was highly expressed in both types of 
astrocytes, but less so in astrocytes during the early process of activation. Ndrg2 was also 
expressed in astrocyte-like cells, but not in neurons, in human brains from PD and 
Cortico-basal degeneration (CBD) patients. In cultured astrocytes, gene silencing of Ndrg2 
significantly enhanced the numbers of 5-bromo-2’-deoxy-uridine (BrdU)-incorporated and 
proliferating cell nuclear antigen (PCNA)-positive cells, and reduced the length of cell 
processes and the amount of F-actin. In contrast, adenovirus-mediated overexpression of 
Ndrg2 significantly reduced the numbers of BrdU-incorporated and PCNA-positive cells, and 
enhanced the amount of F-actin. Fractionation and immunocytochemical analysis further 
revealed that Ndrg2 was located in different cellular fractions including the cytosol and cell 
surface membranes. These results suggest that Ndrg2 may regulate astroglial activation 




1. Introduction   
  
 Astrocytes are ubiquitous in the brain, and have long been considered as structural and 
nutritional supports for neurons. Recent evidence, however, has demonstrated that they also 
play pivotal roles in the maintenance of neuronal activity and survival (for review, Maragakis 
and Rothstein, 2006, Softroniew et al., 2009, Buffo et al., 2010).  They modulate synaptic 
function by transporting the majority of glutamate from the synaptic cleft, balance ions and 
fluid in the extracellular spaces, and regulate blood flow through contact with the brain 
vasculature. In addition to these homeostatic functions in physiological conditions, astrocytes 
respond to all kinds of insults in the central nervous system (CNS), and undergo molecular and 
morphological changes, referred to as reactive astrogliosis or astroglial activation. This process 
involves cell hypertrophy, upregulation of intermediate filaments such as glial fibrillary acidic 
protein (GFAP) and vimentin, and cell proliferation. Activated astrocytes enhance the survival 
of neuronal cells by secreting neurotrophic factors (Maeda et al, 1994) and antioxidants 
(Maragakis and Rothstein, 2006), or by reducing glutamate levels in extracellular spaces.  
However, they also induce the inflammatory response, and release neurotoxic agents such as 
nitric oxide (NO) through up-regulated expression of the inducible NO synthase (iNOS). In 
severe astrogliosis, astrocytes migrate to the border between damaged and healthy areas, and 
form a tight barrier, termed the glial scar. Mature glial scar plays an important role in the 
restriction of inflammation and tissue remodeling in the damaged area, and saving the healthy 
area, although it has inhibitory effects on the axon regeneration and neovascularization (Gadea 
et al., 2008). It is, therefore, essential to properly regulate the level and duration of astroglial 
activation.  
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 N-myc downstream-regulated gene 2 (Ndrg2) is a member of recently identified 
differentiation- and stress- associated genes, and normally expressed in the brain, heart, muscle, 
and to lesser extents in liver and kidney (Qu et al., 2002). An increasing number of reports has 
demonstrated that Ndrg2 had inhibitory effects on the proliferation (Deng et al., 2003, Kim YJ 
et al., 2009) and invasion (Kim A et al., 2009) of tumor cells including glioblastoma. It was 
also reported that Ndrg2 regulated the production of certain secretory proteins in dendritic cells 
(Choi et al., 2007, Choi et al., 2010). In the CNS, Ndrg2 has been reported to be predominantly 
expressed in astrocytes (Nichols, 2003, Okuda et al., 2008), and to a lesser degree in dystrophic 
neurons in Alzheimer’s disease (AD) (Mitchelmore et al., 2004). Ndrg2 was upregulated by 
adrenal steroid hormones (Boulkroun et al., 2002, Nichols, 2003), while downregulated by 
antidepressant and electroconvulsive treatment (Takahashi et al., 2005a). These results suggest 
that Ndrg2 may be involved in the neurodegenerative and neuropsychiatric diseases.  To 
understand the function of Ndrg2 in astrocytes, we studied its expression in both mouse and 





2. Materials and methods 
 
2.1. Cell Cultures and animal experiments 
 Astrocytes were prepared from the cerebral cortex of 1-d old neonatal Wister rats and 
cultured in MEM containing 10% FBS as described previously (Yamaguchi et al, 1999). Rat 
C6 glioma cells were maintained in DMEM containing 10% FBS. Animal experimental 
protocols were approved by the Committee on Animal Experimentation at Kanazawa 
University. All animal experiments were performed using C57BL/6 mice (male, 8-12 week of 
age). A mouse model of Parkinson disease (PD) was created by four sequential intraperitoneal 
injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP; 20 mg/kg, Sigma, St. 
Louis, MO) at 2 h intervals.  
 
2.2. Postmortem specimens 
 Informed consents of using postmortem specimens for biological study were obtained 
from all subjects with a letter of acceptance recognized in the ethics committee of Juntendo 
University School of Medicine. All postmortem specimens were fixed in 20% formalin and 
processed for paraffin-embedding and cut into 6-µm-thick sections.  Samples were subjected to 
immunohistochmical anslysis as described below. 
 
2.3. Reverse transcription polymerase chain reaction (RT-PCR)  
 Total RNA was extracted from cultured astrocytes and striatum using TRIzol 
(Invitrogen, Carlsbad, CA). RT reactions containing 1 g of total RNA were performed using 
PrimeScript (Takara, Shiga, Japan). The individual cDNA species were amplified in a reaction 
mixture containing 1 unit of Taq DNA polymerase (Takara) and specific primers for Ndrg2, 
 6
GFAP, S100, CyclinB1, CyclinD1, CyclinE, p27 and -actin. PCR products were separated 
on a 2% agarose gel. Densitometry was done with the individual PCR products, and 
standardized with -actin.  
 
2.4. Subcellular fractionation 
 The protein samples isolated from rat cultured astrocytes and mouse striatum were 
subfractionated into cytosol (C), membrane (M) and nuclear (N) fractions by solubility-based 
separation and sequential centrifugation using ProteoExtract subcellular fractionation kit 
(EMD Biosciences, Darmstadt, Germany) according to the manufacturer’s instruction.  
 
2.5. Western blotting 
 Cells were solubilized in RIPA buffer containing 10 mM Tris (pH7.6), 1 mM EDTA, 
150 mM NaCl, 1% NP-40, 0.1% sodium dodecylsulfate (SDS), 0.2% sodium deoxycholate, 1 
mM phenylmethylsulfonylfluoride (PMSF), 1 g/ml aprotinin, 10 mM NaF, 1 mM Na3VO4. 
Western blotting was performed using antibodies against Ndrg2 (Santa cruz, Santa cruz, CA), 
Glucose regulated protein (GRP) 78 (Stressgen, Victoria, BC, Canada), GRP75 (Stressgen), 
Cu/Zn superoxide dismutase (SOD) (Stressgen), Glutamate-Aspartate Transporter (GLAST) 
(Millipore, Billerica, MA) and -actin (Sigma). Site of primary antibody binding were 
determined by alkaline phosphatase-conjugated secondary antibodies.  
 
2.6. Immunostaining 
 Brains were removed from C57BL/6 mice (25 to 30 g) after perfusion with 4% 
paraformaldehyde, and cortical sections (10-m) were cut on a cryostat. Sections were 




Ndrg2, GFAP (Daco, Glostrup, Denmark), proliferating cell nuclear antigen (PCNA) (Santa 
cruz) and S100 (Sigma). For human brains, paraffin-embedded sections were deparaffinized, 
and incubated in 3% hydrogen peroxide with methanol for 10minutes to remove endogenous 
peroxidase activity. After preincubation with 5% normal goat serum for 10 minutes, sections 
were incubated with anti-Ndrg2 antibody overnight at 4 ℃. Sections were then subjected to 
further incubation for 1h with biotinylated secondary antibody (DAKO), and for 45 minutes 
with avidin-biotin horseradish complex (ABC) (DAKO) at room tenperature. Finally, 
immunoreactivity was visualized with 0.5mg/ml 3.3.-diaminobenzidine tetrachloride (DAB) 
and 0.3%H2O2. The sections were lightly counterstained with hematoxylin. 
 For immunocytochemistry, cells were fixed with 4% paraformaldehyde and 0.2% 
NP-40, and immunostained using anti-PCNA antibody or anti-BrdU antibody (Daco). FITC- 
or Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, Inc. West 
Grove, PA) was used for visualization of the immunolabeling. 
 
2.7. Recombinant adenovirus 
 A cDNA fragment spanning the entire coding regions of mouse Ndrg2 and the FLAG 
epitope was inserted into the pAxCALNLwtit2 cosmid vector. Recombinant adenovirus 
AxCALNLZ2 Ndrg2 (Ad-Ndrg2) was prepared using an adenovirus expression kit (Takara, 
Tokyo, Japan). Adenovirus was amplified in HEK293 cells. Viral titers were determined by a 
plaque-forming assay in HEK 293 cells. Viral stocks had titers of ~1 x 108 PFU/ml. 
Cre-recombinase expressing adenovirus AxCANCre for the regulation of Ndrg2 expression, 
and a control virus AxCALNLZ2 LacZ (-Galactosidase) were similarly prepared.    
 
2.8. RNA interference 
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Ndrg2-specific siRNAs, siNdrg2-1 (5’-UCAACAGGAGACUUCCAUGGUGUGC 
-3’and 5’-GCACACCAUGGAAGUCUCCUGUUGA-3’) and siNdrg2-2 
(5’-UCAAUUCAGAAUUUCCAGAAAGCUC-3’, 
5’-GAGCUUUCUGGAAAUUCUGAAUUGA-3’), and negative control siRNA (siControl) 
were all obtained from Invitrogen. Mixtures of Ndrg2-1 and Ndrg2-2 or control siRNA were 
transfected into astrocytes by Lipofectamine RNAiMAX (Invitrogen) under the reverse 
transfection protocol according to the manufacturer’s specification.  
 
2.9. Plasmid construction and transfection of cDNA 
Mouse Ndrg2 cDNA encoding the complete open reading frame was amplified by PCR 
and cloned into a pEGFP vector (Invitrogen). The integrity of the insert was verified by DNA 
sequencing. C6 cells were transfected with EGFP or EGFP-Ndrg2 expression vector using 
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s protocol. 
 
2.10. BrdU Labeling 
 Cells were incubated with 10 M 5-bromo-2’-deoxy-uridine (BrdU) (Sigma) for 24 h, 
and then fixed with 4% paraformaldehyde and 0.2% NP-40. After washing twice with PBS, 
cells were treated with 2 N HCl to denature nuclear DNA for 20 min, and then incubated in 0.1 
M sodium tetraborate for 20 min. The cells were subsequently subjected to immunostaining 
with anti-BrdU antibody. The numbers of BrdU-positive cells were normalized by the number 
of DAPI (Invitrogen)-positive cells.  
  




F-actin (Polymerized actin) content was determined as described previously (Ransom 
et al, 2005) with a slight modification. Adenovirus- and siRNA-treated cells were cultured in 
either the presence or absence of serum for 2 days after replating to 96 well plates. Cells were 
fixed with 4% paraformaldehyde and 0.2% NP-40, followed by washing twice with PBS, and 
subsequent staining with TRITC-phalloidin (Sigma) and DAPI for 1 h at room temperature. 
After washing twice with PBS, fluorescence intensity was measured with Fluoroskan Asent FL 
fluorescence microplate fluorometer (Thermo Fisher Scientific Inc., Waltham, MA) with 
excitation at 544 nm and emission at 590 nm. These values were then normalized to DAPI 
fluorescence to yield a measure of total F-actin per cell. 
 
2.12. Evaluation of cell death 
 Cell death was evaluated using LIVE/DEAD assay (Invitrogen) as described before 
(Hori et al., 2004). 
 
2.13. Statistical analysis 
Results are all expressed as the mean ± SE and the statistical significance was 





Expression of Ndrg2 in astrocytes   
 As Ndrg2 was reported to be expressed predominantly in astrocytes in the CNS 
(Nichols, 2003, Okuda et al., 2008), we first studied its expression in the quiescent astrocytes 
in both of the striatum (caudate putamen (CPu)) and the substantia nigra (SN). Ndrg2 was 
expressed in S100-positive astrocytes in both regions (Fig.1 A, B I). The majority of 
S100-positive, Ndrg2-positive astroyctes was GFAP-negative in this condition as previously 
described (Fig.1 A, arrow head, B I, MPTP 0h) (Himeda et al., 2006). 
 Once mice were administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine 
(MPTP), a Parkinson disease (PD)-related neurotoxin, the number of tyrosine hydroxylase 
(TH)-positive dopaminergic neurons was decreased (Fig.1 B 1), and that of GFAP-positive 
astrocytes was increased in both of the SN (Fig.1 B I) and the striatum (Fig.1 B II, C). The 
expression pattern of Ndrg2 was also changed. At early periods (8-24h) after MPTP 
administration, there were a lot of GFAP-positive astrocytes which had reduced levels of 
expression of Ndrg2 (Fig.1 B I, MPTP 1d, B II, MPTP 8h). At a later period (3 days), in 
contrast, the majority of GFAP-positive astrocytes had high levels of Ndrg2 expression (Fig.1 
B I, MPTP 3d, B II, MPTP 3d). Interestingly, in the latter conditions, GFAP- and 
Ndrg2-positive astrocytes tended to accumulate in the substantia nigra pars compacta (SNpc), 
rather than distribute diffusely in the SN (Fig. 1 B I MPTP 3d). Furthermore, the proliferating 
cell nuclear antigen (PCNA)-positive cells which were observed around 8h-3 days after MPTP 
administration had low levels of Ndrg2 expression (Fig.1 B III). RT-PCR analysis with total 
RNA isolated from the striatum confirmed induction of GFAP as well as cell cycle-dependent 




administration. In contrast, expression of Ndrg2 tended to be slightly decreased at 24 h, and 
then increased at 3 days after MPTP administration (Fig.1 C).   
 As it was reported that Ndrg2 was also expressed in dystrophic neurons in Alzheimer’s 
disease (AD) (Mitchelmore et al., 2004), its expression in other neurodegenerative diseases 
including PD was analyzed. Expression of Ndrg2 was not observed in the SNpc from control 
persons, but highly observed in astrocyte-like cells in the SNpc from both PD and 
Cortico-basal degeneration (CBD) patients (Fig. 1 D).  There was no expression of Ndrg2 in 
the neurons including Lewy body (data not shown). 
  
The effect of Ndrg2 expression on the proliferation of astrocytes 
 As Ndrg2 was reported to have growth-inhibitory and apoptosis-inducing effects on 
various types of tumor cells (Deng et al., 2003, Kim YJ et al., 2009) as well as on hepatocytes 
(Yang et al., 2010), the effect of Ndrg2 on astroglial proliferation and apoptosis was analyzed 
using cultured astrocytes isolated from neonatal rats. Transfection of Ndrg2 siRNA (siNdrg2-1, 
-2) effectively reduced the expressions of Ndrg2 protein (Fig. 2 A I) and mRNA (Fig. 2 D), 
when compared to those in the control siRNA-transfected cells (siControl). The mixture of 
siNdrg2-1 and -2 was used for further experiments (siNdrg2). In contrast, infection of 
adenoviruses bearing Cre recombinase (Ad-Cre) and LoxP-Ndrg2 (Ad-Ndrg2) cDNAs 
enhanced the expressions of Ndrg2 protein (Fig. 2 A II) and mRNA (Fig. 2 D) by 
approximately 8 and 6 fold, respectively, when compared to those in control cells (cells with 
infection of Ad-Ndrg2 alone, or cells with infection of both Ad-Cre and Ad-LacZ). 
 Gene silencing of Ndrg2 (siNdrg2) significantly enhanced the numbers of 
BrdU-incorporated and PCNA-positive cells (Fig.2 B, C). In contrast, adenovirus-mediated 
overexpression of Ndrg2 (Ad-Cre Ad-Ndrg2) significantly reduced those numbers, suggesting 
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that Ndrg2 may also have inhibitory effects on the proliferation of astrocytes.   However, 
LIVE/DEAD assay revealed that overexpression of Ndrg2 did not cause cell death in cultured 
astrocytes (data not shown). 
 To dissect the mechanisms underlying the Ndrg2-mediated suppression of astroglial 
proliferation, expressions of cell cycle-associated molecules were analyzed by RT-PCR (Fig. 2 
D). siNdrg2 significantly enhanced some of those transcripts such as CyclinB1 and CyclinE, 
while Ad-Cre Ad-Ndrg2 failed to reduce those transcripts in our system.  
 
The effect of Ndrg2 expression on the morphology of astrocytes 
 As Ndrg2 was also reported to promote neurite outgrowth when overexpressed in PC12 
cells (Takahashi et al., 2005b), the effect of Ndrg2 expression on the morphology of cultured 
astrocytes was analyzed. Gene silencing of Ndrg2 (siNdrg2) was performed as described above, 
and cells were replated on the culture plates at 48 h after transfection. Initial attachment of the 
cells to the plates was observed within 30 min in both siNdrg2 and siControl (Fig.3 A 0.5 h). At 
24 h after plating, however, siNdrg2 showed shorter processes, compared to siControl (Fig.3 A 
24h). Similar tendency was observed until 48 h after plating (data not shown). Consistent with 
these results, F-actin content, determined by phalloidin staining (Ransom et al, 2005), was 
significantly lower in siNdrg2 than in siControl, while enhanced levels of F-actin content were 
observed in Ndrg2-overexpressed cells (Ad-Cre Ad-Ndrg2) (Fig.3 B I). The enhancing effect 
of Ndrg2 on the amount of F-actin were observed both in serum-containing and serum-free 
conditions (Fig.3 B I, B II), suggesting that they may be independent of astroglial growth. To 
clarify whether these changes were associated with astroglial activation, the levels of GFAP 
expression were analyzed by RT-PCR. However, there were no significant differences in all 




   
Intracellular localization of Ndrg2 in astrocytes 
 Although Ndrg2 is considered to be a cytosolic protein, its localization in the nucleus 
(Zhang et al., 2007) and in the cell surface membranes (Takahashi et al., 2005b) was reported 
when overexpressed. To clarify this point in astrocytes, cell fractionation and 
immunocytochemical analysis were performed. The crude fractionation of the samples from 
cultured astrocytes and from mouse striatum revealed that Ndrg2 was located in both of the 
cytosol and the cell membranes (Fig.4 A). The location of Ndrg2 in the nucleus was weakly 
observed in mouse striatum but not in cultured astrycotes (Fig. 4 A). Immunostaining of 
cultured astrocytes with anti-Ndrg2 antibody revealed that Ndrg2 was located in both of the 
perinuclear and leading edge-containing cell surface membranes. In the latter cases, Ndrg2 was 
co-localized with F-actin (Fig.4 B). Similarly, expressions of transfected EGFP-NDRG2, but 




 Reactive astrogliosis is observed in many neurodegenerative conditions including PD. 
Comparing to activated microglia and other inflammatory cells, activated astrocytes have been 
suggested to be more neuroprotective in PD as well as in the experimental models of PD 
(Teismann and Schulz, 2004). To accomplish their protective roles, however, astroglial 
activation should be tightly regulated to prevent toxic hyper-activation.  
 In the current study, we found that Ndrg2 had inhibitory effects on the proliferation of 
astrocytes. In a mouse PD model, reduced levels of expression of Ndrg2 (Fig.1 B I) were 
observed during the period when cell cycle-dependent molecules such as CyclinD1 (Fig.1 C) 
and PCNA (data not shown) were induced. Experiments using cultured astrocytes also 
revealed that the levels of expression of Ndrg2 were inversely associated with the numbers of 
BrdU-incorporated and PCNA-positive cells (Fig.2 B, C). These observations were consistent 
with previous studies in tumor cells (Deng et al., 2003, Kim et al., 2009) and in hepatocytes 
(Yang et al., 2010), although apoptosis was not observed in our system. It was reported that 
Ndrg2 was translocated from the cytosol to the nucleus, and transmitted signals in response to 
hypoxia (Wang et al., 2008), suggesting that Ndrg2 might be directly involved in the signal 
transduction. However, in astrocytes, the effect of Ndrg2 expression on cell cycle-associated 
molecules seemed to be partial (Fig. 2 D), and the location of Ndrg2 in the nucleus was weakly 
observed in mouse striatum, but not in cultured astroytes, suggesting that the underlying 
mechanisms may be more complex.  
 We also found that Ndrg2 had regulatory effects on the morphology of astrocytes. Gene 
silencing of Ndrg2 caused shorter processes (Fig.3 A I, A II) and lower amounts of F-actin 




II). These results were consistent with a previous study in PC 12 cells (Takahashi et al., 2005b), 
and led us to hypothesize that Ndrg2 might be involved in the morphological change 
(hypertrophy) and/or migration during astroglial activation. Our observation that Ndrg2 was at 
least partially located in the cell surface membranes including leading edges (Fig.4 B, C) 
supported this hypothesis. However, the levels of expression of GFAP were not altered by 
either gene silencing or overexpression of Ndrg2 (Fig.3 C), and our preliminary data in 
Scratch-induced migration assay (Etienne-Manneville, 2006) showed no significant difference 
of astroglial migration in control (wild type) cells, Ndrg2-overexpressed cells and 
Ndrg2-knockdown cells. These results suggest that Ndrg2 may not influence hypertrophy or 
migration during astroglial activation, but may rather play a role in the maintenance of 
astroglial morphology under more stable conditions (before and after activation).  
 It was also reported that Ndrg2 was expressed near the neurogenic regions such as the 
subgranular zone of the dentate gyrus and the subventricular zone of the lateral ventricles 
(Nichols, 2003). In these areas, Ndrg2 mRNA was reduced by day 3 after adrenalectomy and 
was restored to the sham-operated levels by corticosterone replacement (Nichols, 2003), 
suggesting that Ndrg2 may be involved in the adrenal steroid-mediated regulation of 
neurogenesis / gliogenesis. Interestingly, our preliminary experiments revealed expression of 
Ndrg2 in Nestin-positive, GFAP-positive progenitor cells in the striatum (Chen et al., 2004) 
after MPTP administration. One of our next goals, therefore, is to clarify the role of Ndrg2 in 
the regulation of neurogenesis / gliogenesis in vivo. 
 In conclusion, we have studied the expression and the effect of expression of Ndrg2 on 
astrocytes.  Ndrg2 may regulate astroglial activation through the suppression of cell 
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Fig. 1. Expression of NDRG2 in a mouse model of PD and human neurodegenerative diseases.  
(A) Ndrg2 expression in quiescent astrocytes. Mouse brain sections including the striatum 
were subjected to immunostaining with anti-Ndrg2 antibody, anti-S100 antibody and 
anti-GFAP antibody. Arrows and arrowheads indicate the cells that do and do not express 
GFAP, respectively. (B) Neurodegeneration and astrogliosis after MPTP injection. Mice 
received four consecutive injections of MPTP (20mg/kg, i.p.) at two-hour intervals. Brain 
sections were prepared at indicated times after the first injection, and subjected to 
immunostaining with anti-Ndrg2 antibody, anti-TH antibody, anti-GFAP antibody and 
anti-PCNA antibody. B I: Substantia nigra, B II, B III: Striatum. In B I and B II, the arrows 
indicate the cells with high levels of expression of  GFAP and low levels of expression of 
Ndrg2.  In B III, the nucleus was stained with DAPI, and PCNA-positive cells are indicated by 
arrow. (C) Gene expression in the process of astrogliosis. Isolated striatum was subjected to 
RNA extraction, followed by RT-PCR with specific primers for Ndrg2, GFAP, S100, 
CyclinD1 and -actin. Values shown are the mean  S.E. in three separate experiments. 
*P<0.05.  (D) Ndrg2 expression in human brains. Post-mortem brain samples from patients 
with PD or CBD were subjected to immunostaining with anti-Ndrg2 antibody. Similar results 
were obtained in three separate sets of experiments.  
 
Fig. 2. Effects of Ndrg2 on the proliferation of astrocytes. 
(A) Gene silencing and overexpression Ndrg2. Cultured rat astrocytes were transfected with 
either control siRNA (siControl) or Ndrg2 siRNA (siNdrg2), or infected with or without 
Ndrg2-expressing adenovirus. Cells were cultured for 2 days after siRNA transfection or 
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adenovirus infection, and lysed in RIPA buffer. Cell lysates were then subjected to Western 
blotting with anti-Ndrg2 antibody. (B) BrdU incorporation. Cells were cultured for 2 days after 
siRNA transfection or adenovirus infection, and subjected to the BrdU labeling followed by the 
immunostaining with anti-BrdU antibody. (C) Determination of proliferating cells. Cells were 
cultured for 2 days after siRNA transfection or adenovirus infection, and subjected to 
immunostaining with anti-PCNA antibody. (D) Expressions of cell cycle-related genes. Cells 
were cultured for 2 days after siRNA transfection or adenovirus infection, and subjected to 
RNA extraction, followed by RT-PCR with specific primers for Ndrg2, CyclinB1, CyclinD1, 
CyclinE1, p27 and -actin. Values shown are the mean  S.E. in four separate experiments. 
*P<0.05, **P<0.01, significantly different from each control value obtained in cells 
transfected control siRNA or cells infected with Ad-Cre and Ad-LacZ. 
 
Fig. 3. Effects of Ndrg2 on the morphology of astrocytes. 
(A) Cellular morphology. Astrocytes were cultured for 2 days after siRNA transfection, 
followed by replating and subsequent observation by phase contrast microscope at indicated 
times. Cells were fixed, and subjected to TRITC-phalloidin staining after 24 h cultivation. (B) 
F-actin content. Astrocytes were replated 24 h after siRNA transfection or adenovirus infection. 
Cells were cultured for 2 days in either the presence or absence of serum, and subjected to 
staining with TRITC-phalloidin for F-actin and DAPI for nuclei. TRITC-phalloidin 
fluorescence was normalized by DAPI fluorescence to yield a measure of total F-actin per cell. 
(C) Expression of GFAP. Cells were subjected to RNA extraction after siRNA transfection or 
adenovirus infection, followed by RT-PCR with specific primers for GFAP and -actin. 




significantly different from each control value obtained in cells transfected with control siRNA 
or cells infected with Ad-Cre and Ad-LacZ. 
 
Fig. 4. Subcellular localization of Ndrg2 in astrocytes. 
(A) Subcellular fractionation. Cultured rat astrocytes or mouse striatum were subjected to 
subcellular fractionation, followed by the determination of protein expression levels for Ndrg2, 
GLAST, GRP75, GRP78, and SOD1 by Western blotting. C: cytosol fraction, M: membrane 
fraction, N: nuclear fraction. (B) Ndrg2 localization in astrocyte. Cultured rat astrocytes were 
subjected to immunostaining with anti-Ndrg2 antibody, and stained with TRITC-phalloidin. 
(C) Ndrg2 localization in Ndrg2-overexpressing C6 glioma cell. C6 cells were transiently 
transfected with EGFP or EGFP-Ndrg2 expression vector. Cells were subjected to Western 
blotting with anti-EGFP antibody (C I) or staining with TRITC-phalloidin, and subsequent 
observation by fluorescence microscope (C II). Similar results were obtained in three separate 
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